NDAORALFILM
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10
Data completeness
6/8 — Strong
SYMPAZAN (clobazam) by Teva is cytochrome p450 2d6 inhibitors [moa]. Approved for epilepsy, dravet syndrome, lennox-gastaut syndrome and 2 more indications. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYMPAZAN (clobazam) is an oral benzodiazepine antiepileptic that works via CYP2D6 inhibition to reduce seizure frequency. It is indicated for multiple severe epilepsy syndromes including Dravet Syndrome, Lennox-Gastaut Syndrome, and refractory epilepsy in pediatric and adult patients. The drug targets patients with treatment-resistant seizure disorders who have failed standard anticonvulsants.
$0.003BPart D
Peak13.7 years to LOEPeak-stage product with modest Part D utilization (1,350 claims in 2023) and limited competitive pressure, suggesting stable but niche market positioning with smaller commercial team requirements.
Mechanism of Action
Cytochrome P450 2D6 Inhibitors
Pharmacologic Class:
Benzodiazepine
Indications (5)
Worked on SYMPAZAN at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.